⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11290049 | 0.80 | — | — | |
| SCHEMBL11322752 | 0.80 | — | — | |
| SCHEMBL7034692 | 0.80 | — | — | |
| SCHEMBL11326387 | 0.80 | — | — | |
| SCHEMBL11335027 | 0.80 | — | — | |
| SCHEMBL9910587 | 0.80 | — | — | |
| SCHEMBL2184363 | 0.79 | — | — | |
| SCHEMBL1337335 | 0.78 | ODC1 (0.43) | — | |
| SCHEMBL1711468 | 0.76 | — | — | |
| SCHEMBL17366114 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101001612-A | Controlled release dosage forms for gamma aminobutyric acid receptor agonists | IMPAX LABORATORIES INC (US) | 2007-07-18 | — | — | CN | disclosed |
| EP-1401423-A4 | METHOD OF TREATING GASTROESOPHAGEAL REFLUX DISEASE AND NOCTURNAL ACID BREAKTHROUGH | DEPOMED DEV LTD (BM) | 2006-08-16 | — | — | EP | disclosed |
| EP-1344524-B1 | Reflux inhibitors | ASTRAZENECA AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| CN-1200713-C | New (aminopropyl) methylphosphinic acids | ASTRAZENECA AB (SE) | 2005-05-11 | — | — | CN | disclosed |
| EP-1401423-A1 | METHOD OF TREATING GASTROESOPHAGEAL REFLUX DISEASE AND NOCTURNAL ACID BREAKTHROUGH | Depomed Development, Ltd (GB) | 2004-03-31 | — | — | EP | disclosed |
| EP-1344524-A1 | Reflux inhibitors | AstraZeneca AB (SE) | 2003-09-17 | — | — | EP | disclosed |
| EP-0936906-B1 | REFLUX INHIBITORS | ASTRAZENECA AB (SE) | 2003-09-10 | — | — | EP | disclosed |
| US-20030162754-A1 | Use of GABA and GABAB agonists | TUFTS UNIVERSITY | 2003-08-28 | — | — | US | disclosed |
| CN-1413104-A | New (aminopropyl) methylphosphinic acids | ASTRAZENECA AB (SE) | 2003-04-23 | — | — | CN | disclosed |
| US-20030031711-A1 | Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough | ASSERTIO THERAPEUTICS, INC. | 2003-02-13 | — | — | US | disclosed |
| WO-2002096404-A1 | METHOD OF TREATING GASTROESOPHAGEAL REFLUX DISEASE AND NOCTURNAL ACID BREAKTHROUGH | DEPOMED DEVELOPMENT LTD (GB) | 2002-12-05 | — | — | WO | disclosed |
| US-6117908-A | Use of GABAB receptor agonists as reflux inhibitors | ASTRA AKTIEBOLAG (SE) | 2000-09-12 | — | — | US | disclosed |
| EP-0936906-A1 | REFLUX INHIBITORS | Astra Aktiebolag (SE) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998011885-A1 | REFLUX INHIBITORS | ASTRA AKTIEBOLAG (SE) | 1998-03-26 | — | — | WO | disclosed |